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Pemetrexed for Heavily Pretreated Patients With
Advanced Non-small Cell Lung Cancer
Jih-Hsiang Lee,1,2 Chong-Jen Yu,3 Kuan-Yu Chen,3 Jin-Yuan Shih,3 Yu-Lin Lin,1 Chih-Hsin Yang1,2,4*
Background/Purpose: The efficacy and safety of chemotherapy as third- or higher-line therapy for advanced
non-small cell lung cancer (NSCLC) are unclear. The purpose of this study was to evaluate the efficacy and
safety of pemetrexed for heavily pretreated, advanced NSCLC.
Methods: We retrospectively reviewed advanced NSCLC patients who received pemetrexed and more than
two prior chemotherapy regimens. The tumor responses were evaluated by the Response Evaluation Criteria
of Solid Tumors. Progression-free survival and overall survival were calculated by the Kaplan–Meier method.
Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events version 3.0.
Results: A total of 95 patients (53 men and 42 women) were included. The median age was 63 years (range,
29–83). Seventy (73.7%) patients had adenocarcinoma. The median number of prior systemic therapies
was three (range, 2–7). The median number of cycles of pemetrexed therapy was four (range, 1–11). Seven
(7.4%) patients achieved a partial response, and 33 (34.7%) had stable disease. The median progression-free
survival was 116 days, and the median overall survival was 382 days. A trend toward increased progression-
free survival was observed for patients who had non-squamous compared with squamous NSCLC.
Conclusion: Pemetrexed has modest efficacy for heavily pretreated NSCLC patients.
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Non-small cell lung cancer (NSCLC) is one of the
most common malignancies worldwide.1 Systemic
therapy, either chemotherapy or targeted ther-
apy, is the main treatment strategy for advanced
NSCLC.2,3 Platinum-based doublet chemother-
apy is often prescribed as first-line therapy for
NSCLC, followed by single agent docetaxel4,5 or
pemetrexed6 at the time of progression. Gefitinib
was approved in Asia and Europe, especially for
NSCLC harboring epidermal growth factor recep-
tor mutation.7 Erlotinib was used as second or
third line therapy in Asia and United States.3,8
Currently, there is no standard third-line chemo-
therapy for NSCLC.9
Pemetrexed is a novel multi-targeted antifo-
late which inhibits dihydrofolate reductase, thymi-
dylate synthase, and glycinamide ribonucleotide
formyltransferase.10 Pemetrexed has become a
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standard first- or second-line therapies for NSCLC
patients11 and has recently been approved as main-
tenance treatment after first-line chemotherapy.12
For chemotherapy-naïve NSCLC patients, the over-
all survival for pemetrexed plus cisplatin or car-
boplatin is not inferior to that with gemcitabine
plus cisplatin13 or carboplatin;14 the incidence 
of hematological toxicity with pemetrexed-based
treatment is less than with gemcitabine-based
treatment.13,14 As second-line therapy, pemetrexed
and docetaxel offer comparable efficacy to NSCLC
patients who have progressed on first-line chemo-
therapy.6 Pemetrexed has the advantage of low
hematological toxicity compared with docetaxel.
As a result of its low toxicity, single-agent peme-
trexed is the ideal choice for heavily pretreated
NSCLC patients, and the objective of this study was
to evaluate its efficacy and safety in these patients.
Materials and Methods
Study design and patient selection
We searched the complete National Taiwan Uni-
versity Cancer Registry for NSCLC patients who
had received pemetrexed therapy, and reviewed
their pharmacy records from July 1, 2005 to
December 31, 2006. The inclusion criteria for
this study were NSCLC patients who received at
least two lines of prior systemic therapy (chemo-
therapy or targeted therapy) and at least one
chemotherapy regimen. Patients who had enrolled
in other pemetrexed-related clinical trials were
excluded from the analysis. Recorded items in-
cluded sex, age, smoking history, histopathological
type of NSCLC, prior systemic therapy regimens,
and other demographic factors.
The dose, schedule, number of cycles, and dose
modification of pemetrexed were recorded. A dose
delay was defined as an interval of > 4 weeks 
between two pemetrexed treatments.
Tumor response was retrospectively evaluated
according to the Response Evaluation Criteria in
Solid Tumors. Progression-free survival was de-
fined as the time from initiation of pemetrexed
to the date of documented progressive disease or
the patient’s death. Overall survival was defined
as the duration between initiation of pemetrexed
treatment and the patient’s death.
The adverse effects in the medical records were
coded according to the Common Terminology
Criteria for Adverse Event version 3.0.
Patient characteristics
A total of 95 patients (53 men and 42 women)
met the enrollment criteria for our analysis. Their
characteristics are listed in Table 1. The median
number of therapy regimens prior to pemetrexed
treatment was three for all patients, and two for
those for whom epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) were not
regarded as one line of therapy. The prior thera-
pies are listed in Table 2.
Treatment
All patients received a full dose of vitamin B12 and
folic acid supplement before and during peme-
trexed treatment. All patients except one received
the recommended 500 mg/m2 pemetrexed as an
Table 1. Patient characteristics (n = 95)*
Variables
Age (yr) 63 (29–83)
Sex
Male 53 (55.8)
Female 42 (44.2)
Smoking status
Smoker 38 (40.0)
Non-smoker 57 (60.0)
Histopathology
Adenocarcinoma 70 (73.7)
Squamous cell carcinoma 12 (12.6)
Others† 13 (13.7)
ECOG performance status
0 2 (2.1)
1 53 (55.9)
2 36 (37.9)
3 3 (3.2)
4 1 (1.1)
*Data presented as median (range) or n (%); †include poorly-
differentiated or unclassified non-small cell lung cancer. ECOG =
Eastern Cooperative Oncology Group.
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initial dose. Seventy-five (78.9%) patients received
the same dose in the following cycles. Eighteen
(18.9%) patients received an escalated dose of
pemetrexed in the following cycles, with a maxi-
mum of 787 mg/m2. Dose reduction was carried
out for one patient because of grade 3 hemato-
logical toxicity. One patient received 333 mg/m2
(500 mg) per cycle. One patient received cisplatin
along with pemetrexed therapy, and three received
uracil/tegafur accompanied with pemetrexed. A
median four cycles of pemetrexed were prescribed
(range, 1–11).
Statistical analysis
Statistical analyses were carried out using SPSS ver-
sion 17.0 (SPSS, Chicago, IL, USA). The Kaplan–
Meier method was used to estimate overall survival
and progression-free survival. Log-rank test was
used to compare survival of patients with different
clinicopathological factors. All p values were
two-sided and a value of < 0.05 was considered
as statistically significant.
Results
Efficacy
Seven (7.4%) patients achieved a partial response
and 33 (34.7%) had stable disease as best re-
sponse. The overall disease control rate (partial
response plus stable disease) was 42.1%. Forty-
eight (50.5%) patients had progressive disease
after pemetrexed treatment. Seven (7.4%) pa-
tients did not have adequate imaging studies to
evaluate treatment response.
With a median follow-up of 253 days, the
median progression-free survival was 116 days
(range, 8–432 days). The median overall survival
was 382 days (range, 8–575 days) (Figure 1). Many
patients received EGFR-TKIs before pemetrexed
administration. Therefore, we tested whether prior
EGFR-TKIs influenced the treatment outcome of
pemetrexed. The median progression-free survival
of patients who received prior EGFR-TKIs and
those who did not was 114 and 65 days, respec-
tively (p = 0.36). The overall survival was 382 
and 339 days, respectively (p = 0.72) (Figure 2).
We performed subgroup analysis according to
NSCLC histological type. The progression-free
survival for non-squamous NSCLC was 116 days
compared with 40 days for squamous NSCLC
(p = 0.14). The overall survival was 382 days for
non-squamous NSCLC and 295 days for squa-
mous NSCLC (p = 0.74).
Toxicity
The toxicity of pemetrexed included anemia,
leukopenia, gastrointestinal infection, abnormal
liver function, and respiratory discomfort. Table 3
lists the toxicities that were grade 3 or higher.
Infection was the most common serious toxicity
and accounted for three possible treatment-related
deaths (2 from pneumonia and 1 from septic
shock). Elevation of alanine transaminase was
noted in 26 patients (27.4%), but only four of
them (4.2%) were grade 3 or higher. One woman
Table 2. Numbers and regimens of prior therapies
Number of prior therapies*
1 0:14
2 23:53
3 47:16
4 15:10
5 9:2
6 1:0
Chemotherapy†
Cisplatin 89 (93.7)
Carboplatin 5 (5.3)
Gemcitabine 86 (90.5)
Docetaxel 69 (72.6)
Vinorelbine 26 (27.4)
Uracil/Tegafur 14 (14.7)
Paclitaxel 13 (13.7)
Etoposide 11 (11.6)
Epirubicin 6 (6.3)
Bevacizumab 1 (1.1)
Cetuximab 1 (1.1)
EGFR TKIs 76 (80.0)
Gefitinib 70 (73.7)
Erlotinib 13 (13.7)
*Data presented as TKI included: TKI excluded; or †n (%). EGFR
TKIs = epidermal growth factor receptor tyrosine kinase inhibitor.
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died of a catheter-related complication (perfora-
tion of the superior vena cava).
Discussion
In our study, the response rate for pemetrexed 
in heavily pretreated NSCLC patients was 7.4%,
progression-free survival was 3.8 months, and
overall survival was 12.5 months. According to the
results of two large randomized controlled trials,
the response rate for best supportive care for
NSCLC patients who had received more than two
lines of therapy was < 1.3%, progression-free sur-
vival was 1.8–2.6 months, and overall survival was
4.7–5.1 months.8,15 Compared with historical con-
trols, our study suggested that pemetrexed offers
some benefit to heavily pretreated NSCLC patients.
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Figure 1. Kaplan–Meier curves of (A) progression-free survival and (B) overall survival. Vertical lines indicate censored
observation.
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Figure 2. Kaplan–Meier curves stratified by prior epidermal growth factor receptor tyrosine kinase inhibitor exposure.
(A) Progression-free survival (p=0.36) and (B) overall survival (p=0.72). Solid line, EGFR-TKIs exposure prior to pemetrexed
therapy; dashed line, no EGFR-TKI exposure prior to pemetrexed therapy. Vertical lines indicate censored observations.
EGFR-TKIs = Epidermal growth factor receptor tyrosine kinase inhibitors.
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The role of third- or higher-line chemother-
apy for NSCLC patients is still controversial. To
date, as far as we are aware, there has been no
prospective phase II or III trial to evaluate the
safety and efficacy of cytotoxic agents as third- or
higher-line therapy. In a small retrospective study,
Ozdogan et al suggested that third-line chemo-
therapy is feasible for selected NSCLC patients.16
However, the improvement in survival beyond
that with second-line chemotherapy was only
modest.17 Many patients did not receive third-line
treatment because of a decline in performance
status. Therefore, treatment efficacy, tolerability,
and other factors such as convenience should 
be considered when preparing to prescribe cyto-
toxic agents to heavily pretreated NSCLC pa-
tients.2 As second-line therapy, pemetrexed has
less toxicity than docetaxel and has similar effi-
cacy, even for elderly patients.6,18 A retrospective
study has shown that second- or third-line therapy
with pemetrexed is safe and might offer better
progression-free survival in patients with good
performance status.19 Our study suggested that
pemetrexed was well tolerated as third- or higher-
line therapy for NSCLC, even though 42% patients
had an Eastern Cooperative Oncology Group per-
formance status of ≥ 2. In the present study, 97.9%
of patients received the recommended (500 mg/
m2) or higher dose of pemetrexed. Schedule de-
lay was necessary in only 17.9% patients, which
was similar to that in a previous trial in which
pemetrexed was administrated as second-line
therapy.20 To the best of our knowledge, our study
is the largest, although retrospective, case series
to evaluate the safety and efficacy of a cytotoxic
agent in heavily pretreated NSCLC patients. The
role of pemetrexed as third- or higher-line therapy
in NSCLC should be confirmed by prospective
studies.
The overall survival in our study was 12.5
months, which was longer than that in a previ-
ous trial in which pemetrexed was administrated
as second-line therapy for NSCLC.6 The overall
response rate in our study was only 7.4%, and
50.5% of patients had progressive disease after
pemetrexed therapy. The progression-free sur-
vival in our study was 3.8 months, which is sim-
ilar to that in other studies.6,20,21 It is possible
that ethnic difference, but not pemetrexed ther-
apy, might be responsible for the differences in
overall survival. Asian NSCLC patients might live
longer than their Caucasian counterparts. This
has also been demonstrated in the subgroup an-
alysis of a randomized phase III trial, which eval-
uates the efficacy of cetuximab for therapy-naïve
NSCLC patients and in which the median sur-
vival of Asian and Caucasian NSCLC patients was
19.5 and 9.6 months, respectively. As for peme-
trexed, a randomized phase III trial of pemetrexed
as second-line therapy in Caucasian patients with
NSCLC showed that the median survival was
6.7–6.9 months.20 However, a similarly designed
randomized trial conducted in Japan showed
that the overall survival of pretreated NSCLC pa-
tients who received pemetrexed was 12.6–16.0
months.21 Therefore, ethnic difference is a plausi-
ble explanation for the long survival time ob-
served in the present study. Salvage therapy with
Table 3. Serious adverse events during
pemetrexed treatment
Adverse event Grade 3 Grade 4 Grade 5
Hematological
Anemia 2 0 0
Leukopenia 1 0 0
Gastrointestinal
Diarrhea 2 1 0
Nausea 1 0 0
Vomiting 1 0 0
Infectious
Pneumonia 1 4 2
Sepsis 0 1 1
Hepatobiliary
ALT 3 1 0
Respiratory
ILD 0 1 0
Dyspnea 1 4 0
Vascular
Venous injury 0 0 1
ALT = Alanine transaminase; ILD = interstitial lung disease.
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EGFR-TKIs after pemetrexed failure has also been
postulated to be responsible for the ethnic dif-
ference.22 The overall survival in our study, how-
ever, was comparable to the that in the above
Japanese study,21 even though 80% of our pa-
tients received EGFR-TKIs prior to pemetrexed
therapy (Table 2). There was no difference in
progression-free survival and overall survival with
regard to prior EGFR-TKI exposure (Figure 2).
Factors other than EGFR-TKI exposure seemed to
contribute to the long survival time. A study of
the underlying mechanism responsible for this
difference is warranted.
Our study had several limitations. First, selec-
tion bias could have been introduced into the
retrospective study because patients with rapidly
progressive NSCLC might not have had the choice
to receive third-line therapy. However, this selec-
tion bias might have existed in all studies that
have explored the role of third-line therapy.
Second, some toxicity might have been evaluated
or recorded inadequately and retrospectively.
Some data were not collected regularly and com-
prehensively, therefore, the incidence of toxicity
might have been underestimated. For example,
grade 3 or more elevation alanine transaminase
developed in 4.2% of our patients, whereas this
toxicity developed in 8.1–20.0% of patients in
many other prospective studies.21,23–25 In order
to evaluate patient tolerance and overall toxicity
more precisely, dose-reduction and schedule-
delay rates were used as surrogates. Only one 
patient received a reduced dose of pemetrexed
because of toxicity, and 78 (82.1%) received
treatment as scheduled. The dose-reduction and
schedule-delay rates in our study were similar to
those in a prospective randomized phase III trial,20
although more patients with poor performance
status were enrolled in our study. Therefore, we
believed that the administration of pemetrexed
in our study was as safe as in other prospective
studies.
In summary, the results of the present retro-
spective study suggest that pemetrexed has mod-
est efficacy and an acceptable toxicity profile in
heavily pretreated NSCLC patients.
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